Becton Dickinson and Co. (BD) has reached a settlement with the U.S. Securities and Exchange Commission (SEC) over allegations that it misled investors regarding the risks associated with its Alaris infusion pump. The company has agreed to pay a fine of $175 million to resolve these charges, which also included claims of overstating income. The SEC announced the settlement on December 16, 2024. In a separate case, drugmaker Sandoz has entered into a $275 million settlement to address an antitrust lawsuit, although it does not admit to any wrongdoing related to the allegations, which include price-fixing of generic drugs.